At its annual shareholders' meeting Thursday, MedImmune ( MEDI) reiterated the financial guidance the biotech company issued last month. For 2003, the company expects total revenue of $1.08 billion to $1.13 billion, which would represent growth of 27% to 33% over 2002, and earnings of 84 cents to 89 cents a share, compared with a loss of $4.40 a share last year. On an adjusted basis, excluding various items, the company expects to earn 88 cents to 93 cents for this year. MedImmune expects to report a loss of a penny a share to a profit of 1 cent a share for the quarter ending June 30, and on an adjusted basis, the company believes it will report anywhere from break-even to net income of 2 cents a share. On average, analysts polled by Thomson First Call are expecting the company to earn 1 cent in the second quarter and 90 cents for the year. Shareholders also approved all proposals outlined in MedImmune's 2003 proxy statement, including the re-election of the board of directors and the ratification of PricewaterhouseCoopers as the company's auditors. Shares of MedImmune were up $1.12, or 3.4%, to $33.90.